Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei

Jason E. Cummings, Adam J. Beaupre, Susan E. Knudson, Nina Liu, Weixuan Yu, Carla Neckles, Hui Wang, Avinash Khanna, Gopal R. Bommineni, Lily A. Trunck, Herbert P. Schweizer, Peter J. Tonge, Richard A. Slayden

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Identification of a novel class of anti-Burkholderia compounds is key in addressing antimicrobial resistance to current therapies as well as naturally occurring resistance. The FabI enoyl-ACP reductase in Burkholderia is an underexploited target that presents an opportunity for development of a new class of inhibitors. A library of substituted diphenyl ethers was used to identify FabI1-specific inhibitors for assessment in Burkholderia pseudomallei ex vivo and murine efficacy models. Active FabI1 inhibitors were identified in a two-stage format consisting of percent inhibition screening and MIC determination by the broth microdilution method. Each compound was evaluated against the B. pseudomallei 1026b (efflux-proficient) and Bp400 (efflux-compromised) strains. In vitro screening identified candidate substituted diphenyl ethers that exhibited MICs of less than 1 μg/ml, and enzyme kinetic assays were used to assess potency and specificity against the FabI1 enzyme. These compounds demonstrated activity in a Burkholderia ex vivo efficacy model, and two demonstrated efficacy in an acute B. pseudomallei mouse infection model. This work establishes substituted diphenyl ethers as a suitable platform for development of novel anti-Burkholderia compounds that can be used for treatment of melioidosis.

Original languageEnglish (US)
Pages (from-to)1646-1651
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number3
DOIs
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

Phenyl Ethers
Burkholderia pseudomallei
Burkholderia
Melioidosis
Enzyme Assays
Libraries
Oxidoreductases
Enzymes
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Cummings, J. E., Beaupre, A. J., Knudson, S. E., Liu, N., Yu, W., Neckles, C., ... Slayden, R. A. (2014). Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy, 58(3), 1646-1651. https://doi.org/10.1128/AAC.02296-13

Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. / Cummings, Jason E.; Beaupre, Adam J.; Knudson, Susan E.; Liu, Nina; Yu, Weixuan; Neckles, Carla; Wang, Hui; Khanna, Avinash; Bommineni, Gopal R.; Trunck, Lily A.; Schweizer, Herbert P.; Tonge, Peter J.; Slayden, Richard A.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 3, 03.2014, p. 1646-1651.

Research output: Contribution to journalArticle

Cummings, JE, Beaupre, AJ, Knudson, SE, Liu, N, Yu, W, Neckles, C, Wang, H, Khanna, A, Bommineni, GR, Trunck, LA, Schweizer, HP, Tonge, PJ & Slayden, RA 2014, 'Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei', Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1646-1651. https://doi.org/10.1128/AAC.02296-13
Cummings, Jason E. ; Beaupre, Adam J. ; Knudson, Susan E. ; Liu, Nina ; Yu, Weixuan ; Neckles, Carla ; Wang, Hui ; Khanna, Avinash ; Bommineni, Gopal R. ; Trunck, Lily A. ; Schweizer, Herbert P. ; Tonge, Peter J. ; Slayden, Richard A. / Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 3. pp. 1646-1651.
@article{5ef67485499d4dc0bf944136aae4bafd,
title = "Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei",
abstract = "Identification of a novel class of anti-Burkholderia compounds is key in addressing antimicrobial resistance to current therapies as well as naturally occurring resistance. The FabI enoyl-ACP reductase in Burkholderia is an underexploited target that presents an opportunity for development of a new class of inhibitors. A library of substituted diphenyl ethers was used to identify FabI1-specific inhibitors for assessment in Burkholderia pseudomallei ex vivo and murine efficacy models. Active FabI1 inhibitors were identified in a two-stage format consisting of percent inhibition screening and MIC determination by the broth microdilution method. Each compound was evaluated against the B. pseudomallei 1026b (efflux-proficient) and Bp400 (efflux-compromised) strains. In vitro screening identified candidate substituted diphenyl ethers that exhibited MICs of less than 1 μg/ml, and enzyme kinetic assays were used to assess potency and specificity against the FabI1 enzyme. These compounds demonstrated activity in a Burkholderia ex vivo efficacy model, and two demonstrated efficacy in an acute B. pseudomallei mouse infection model. This work establishes substituted diphenyl ethers as a suitable platform for development of novel anti-Burkholderia compounds that can be used for treatment of melioidosis.",
author = "Cummings, {Jason E.} and Beaupre, {Adam J.} and Knudson, {Susan E.} and Nina Liu and Weixuan Yu and Carla Neckles and Hui Wang and Avinash Khanna and Bommineni, {Gopal R.} and Trunck, {Lily A.} and Schweizer, {Herbert P.} and Tonge, {Peter J.} and Slayden, {Richard A.}",
year = "2014",
month = "3",
doi = "10.1128/AAC.02296-13",
language = "English (US)",
volume = "58",
pages = "1646--1651",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei

AU - Cummings, Jason E.

AU - Beaupre, Adam J.

AU - Knudson, Susan E.

AU - Liu, Nina

AU - Yu, Weixuan

AU - Neckles, Carla

AU - Wang, Hui

AU - Khanna, Avinash

AU - Bommineni, Gopal R.

AU - Trunck, Lily A.

AU - Schweizer, Herbert P.

AU - Tonge, Peter J.

AU - Slayden, Richard A.

PY - 2014/3

Y1 - 2014/3

N2 - Identification of a novel class of anti-Burkholderia compounds is key in addressing antimicrobial resistance to current therapies as well as naturally occurring resistance. The FabI enoyl-ACP reductase in Burkholderia is an underexploited target that presents an opportunity for development of a new class of inhibitors. A library of substituted diphenyl ethers was used to identify FabI1-specific inhibitors for assessment in Burkholderia pseudomallei ex vivo and murine efficacy models. Active FabI1 inhibitors were identified in a two-stage format consisting of percent inhibition screening and MIC determination by the broth microdilution method. Each compound was evaluated against the B. pseudomallei 1026b (efflux-proficient) and Bp400 (efflux-compromised) strains. In vitro screening identified candidate substituted diphenyl ethers that exhibited MICs of less than 1 μg/ml, and enzyme kinetic assays were used to assess potency and specificity against the FabI1 enzyme. These compounds demonstrated activity in a Burkholderia ex vivo efficacy model, and two demonstrated efficacy in an acute B. pseudomallei mouse infection model. This work establishes substituted diphenyl ethers as a suitable platform for development of novel anti-Burkholderia compounds that can be used for treatment of melioidosis.

AB - Identification of a novel class of anti-Burkholderia compounds is key in addressing antimicrobial resistance to current therapies as well as naturally occurring resistance. The FabI enoyl-ACP reductase in Burkholderia is an underexploited target that presents an opportunity for development of a new class of inhibitors. A library of substituted diphenyl ethers was used to identify FabI1-specific inhibitors for assessment in Burkholderia pseudomallei ex vivo and murine efficacy models. Active FabI1 inhibitors were identified in a two-stage format consisting of percent inhibition screening and MIC determination by the broth microdilution method. Each compound was evaluated against the B. pseudomallei 1026b (efflux-proficient) and Bp400 (efflux-compromised) strains. In vitro screening identified candidate substituted diphenyl ethers that exhibited MICs of less than 1 μg/ml, and enzyme kinetic assays were used to assess potency and specificity against the FabI1 enzyme. These compounds demonstrated activity in a Burkholderia ex vivo efficacy model, and two demonstrated efficacy in an acute B. pseudomallei mouse infection model. This work establishes substituted diphenyl ethers as a suitable platform for development of novel anti-Burkholderia compounds that can be used for treatment of melioidosis.

UR - http://www.scopus.com/inward/record.url?scp=84896899987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896899987&partnerID=8YFLogxK

U2 - 10.1128/AAC.02296-13

DO - 10.1128/AAC.02296-13

M3 - Article

C2 - 24379198

AN - SCOPUS:84896899987

VL - 58

SP - 1646

EP - 1651

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -